Outcome measures
hyperemia
ADVERSE EVENTS, HYPEREMIA, SECONDARY
The primary endpoints were corneal and conjunctival staining score, OSDI score, drug tolerance, and adherence rates at 12-week visits. The secondary efficacy endpoints—corneal and conjunctival staining score, OSDI score at 4-week visits and IOP, TBUT, and bulbar/limbal hyperemia score at the 4- and 12–week visits were analyzed and compared between the groups. For safety assessment, BCVA, SBP, DBP, HR, and physical examination at 4 and 12 weeks and adverse events during the whole study period were analyzed.